Project

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Ongoing - recruitment active · 2024 until 2028

Schittenhelm Marcus, Dei Cas Alissa